Toxicities with targeted therapies after immunotherapy in metastatic melanoma

Nicole Grogan; Umang Swami; Aaron D Bossler; Yousef Zakharia; Mohammed Milhem

doi:10.1097/CMR.0000000000000493

Back

Toxicities with targeted therapies after immunotherapy in metastatic melanoma

Journal article

Peer reviewed

Toxicities with targeted therapies after immunotherapy in metastatic melanoma

Nicole Grogan, Umang Swami, Aaron D Bossler, Yousef Zakharia and Mohammed Milhem

Melanoma research, Vol.28(6), pp.600-604

12/2018

DOI: 10.1097/CMR.0000000000000493

PMCID: PMC6436382

PMID: 30086073

View Online

Abstract

Over the last decade, melanoma treatment has taken rapid strides with the advent of immunotherapies and targeted agents. With these new agents, there has been a significant improvement in patient survival. However, these new treatment options may sometimes lead to unanticipated side effects that make these treatments challenging to administer and monitor. In preclinical studies, BRAF and MEK inhibitors have shown to modulate tumor microenvironment and potentiate immunotherapies. Therefore, some patients who had prior treatment with immunotherapies can develop immune toxicities even with these targeted agents due to the long half-life of these monoclonal antibodies. Herein, we present our institutional experience with regard to these unexpected toxicities with targeted agents in patients who had previous treatment with immunotherapies. This case series lays out the various side effects along with details of their management, outcomes, and patient response.

Skin Neoplasms - pathology

Antineoplastic Agents, Immunological - toxicity

Melanoma - complications

Immunotherapy - methods

Skin Neoplasms - drug therapy

Humans

Middle Aged

Male

Melanoma - pathology

Skin Neoplasms - complications

Neoplasm Metastasis

Melanoma - drug therapy

Aged, 80 and over

Adult

Female

Aged

Details

Title: Subtitle: Toxicities with targeted therapies after immunotherapy in metastatic melanoma
Creators: Nicole Grogan - Departments of Internal Medicine
Umang Swami - Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine
Aaron D Bossler - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
Yousef Zakharia - Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine
Mohammed Milhem - Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Carver College of Medicine
Resource Type: Journal article
Publication Details: Melanoma research, Vol.28(6), pp.600-604
DOI: 10.1097/CMR.0000000000000493
PMID: 30086073
PMCID: PMC6436382
NLM abbreviation: Melanoma Res
ISSN: 0960-8931
eISSN: 1473-5636
Publisher: England
Grant note: P30 CA086862 / NCI NIH HHS
Language: English
Date published: 12/2018
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Internal Medicine
Record Identifier: 9984047623202771

Metrics

27 Record Views

9 Times Cited - Web of Science

See more details